1
|
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, Kalyon H, Akay OM, Deveci B, Bekoz H, Sevindik OG, Toptas T, Yilmaz F, Koyun D, Alkis N, Alacacioglu I, Sonmez M, Yavasoglu I, Tombak A, Mehtap O, Kurnaz F, Yuce OK, Karakus V, Turgut M, Kurekci DD, Ayer M, Keklik M, Buyuktas D, Ozbalak M, Ferhanoglu B. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. Hematol Oncol 2023; 41:663-673. [PMID: 37211991 DOI: 10.1002/hon.3174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 03/24/2023] [Accepted: 05/02/2023] [Indexed: 05/23/2023]
Abstract
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.
Collapse
Affiliation(s)
- Elif Birtas Atesoglu
- Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey
| | - Zafer Gulbas
- Division of Hematology, Anadolu Medical Center, Kocaeli, Turkey
| | - Ant Uzay
- Division of Hematology, Acibadem Atakent Hospital, Istanbul, Turkey
| | - Muhit Ozcan
- Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey
| | - Fahir Ozkalemkas
- Department of Internal Medicine, Division of Hematology, Uludag University Medical Faculty, Bursa, Turkey
| | - Mehmet Sinan Dal
- Division of Hematology, Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara, Turkey
| | - Hakan Kalyon
- Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey
| | - Olga Meltem Akay
- Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey
| | - Burak Deveci
- Division of Hematology, Medstar Hospital, Antalya, Turkey
| | - Huseyin Bekoz
- Department of Internal Medicine, Division of Hematology, Medipol University Medical Faculty, Istanbul, Turkey
| | - Omur Gokmen Sevindik
- Department of Internal Medicine, Division of Hematology, Medipol University Medical Faculty, Istanbul, Turkey
| | - Tayfur Toptas
- Department of Internal Medicine, Division of Hematology, Marmara University Medical Faculty, Istanbul, Turkey
| | - Fergun Yilmaz
- Department of Internal Medicine, Division of Hematology, Marmara University Medical Faculty, Istanbul, Turkey
| | - Derya Koyun
- Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey
| | - Nihan Alkis
- Division of Hematology, Bursa City Hospital, Bursa, Turkey
| | - Inci Alacacioglu
- Department of Internal Medicine, Division of Hematology, Dokuz Eylul University Medical Faculty, Izmir, Turkey
| | - Mehmet Sonmez
- Department of Internal Medicine, Division of Hematology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - Irfan Yavasoglu
- Department of Internal Medicine, Division of Hematology, Adnan Menderes University Medical Faculty, Aydin, Turkey
| | - Anil Tombak
- Department of Internal Medicine, Division of Hematology, Mersin University Medical Faculty, Mersin, Turkey
| | - Ozgur Mehtap
- Department of Internal Medicine, Division of Hematology, Kocaeli University Medical Faculty, Kocaeli, Turkey
| | - Fatih Kurnaz
- Division of Hematology, Kocaeli Medicalpark Hospital, Kocaeli, Turkey
| | - Orhan Kemal Yuce
- Department of Internal Medicine, Division of Hematology, Akdeniz University Medical Faculty, Antalya, Turkey
| | - Volkan Karakus
- Division of Hematology, Antalya Research and Training Hospital, Antalya, Turkey
| | - Mehmet Turgut
- Department of Internal Medicine, Division of Hematology, Ondokuzmayıs University Medical Faculty, Samsun, Turkey
| | - Derya Deniz Kurekci
- Department of Internal Medicine, Division of Hematology, Ondokuzmayıs University Medical Faculty, Samsun, Turkey
| | - Mesut Ayer
- Division of Hematology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey
| | - Muzaffer Keklik
- Department of Internal Medicine, Division of Hematology, Erciyes University Medical Faculty, Kayseri, Turkey
| | - Deram Buyuktas
- Division of Hematology, V.K.V. American Hospital, Istanbul, Turkey
| | - Murat Ozbalak
- Division of Hematology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey
| | - Burhan Ferhanoglu
- Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey
| |
Collapse
|
2
|
Gundogdu H, Alkis N, Bozkirli B, Yilmaz K, Aksoy M, Gunaydin S, Akbuga G. Status of ERAS implementation in Turkey: The outcomes of a nationwide survey. Clin Nutr ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.06.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Abstract
Viral infections emerge in the pathogenesis of subacute thyroiditis. Aside from this, subacute thyroiditis following vaccines utilizing inactivated viruses has been shown on rare occasions. Due to the COVID-19 pandemic, several vaccines have been developed all over the world; mass and unprecedented vaccination has thus been initiated. However, it is known that cases such as subacute thyroiditis have been reported, albeit rarely, after administration of COVID-19 vaccines. In this case report, we present a 59-year-old patient with multiple myeloma developing subacute thyroiditis following BNT162b2 vaccine. Patient had swelling in the neck, and his symptoms were controlled with non-steroidal anti-inflammatory drugs. Subacute thyroiditis following administration of the COVID-19 vaccine is rare; however, it is likely an under-reported condition that is difficult to detect. Clinicians should stay informed and have increased awareness of post-COVID-19 vaccine subacute thyroiditis.
Collapse
Affiliation(s)
- Nihan Alkis
- Department of Hematology, Bursa City Hospital, Bursa, Turkey
| | - Mehmet Baysal
- Department of Hematology, Bursa City Hospital, Bursa, Turkey
| |
Collapse
|
4
|
Ulas A, Bilici A, Tokluoglu S, Akinci S, Silay K, Paksoy Turkoz F, Durnali A, Oksuzoglu B, Alkis N. Risk Factors for Skeletal-Related Events in Patients with Non-Small Cell Lung Cancer Patients with Bone Metastases. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Ulas A, Tokluoglu S, Kös M, Silay K, Akinci S, Oksuzoglu B, Alkis N. Lung Cancer in Women, a Different Disease: Survival Differences by Sex. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv049.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Ozatli T, Yalcintas Arslan U, Ekinci A, Bal O, Esbah O, Basal F, Eraslan E, Alkis N, Oksuzoglu B. A Retrospective Evaluation of Efficacy and Tolerability of Two Different Adjuvant Chemoradiotherapy Regimens in Operable Node-Positive Gastric Carcinoma with D2 Lymph Node Dissection. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Dalkilic E, Bulbul Baskan E, Alkis N, Gullulu M, Yavuz M, Dilek K, Ersoy A, Yurtkuran M. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod Rheumatol 2014. [DOI: 10.3109/s10165-011-0590-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, Bekar A, Deligonul A, Hartavi M, Alkis N, Manavoglu O. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol 2013; 16:173-7. [PMID: 23740136 DOI: 10.1007/s12094-013-1059-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Accepted: 05/21/2013] [Indexed: 10/26/2022]
Abstract
BACKGROUND AND AIMS Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols. METHODS Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 ± 12.9 years, age range: 23-81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. RESULTS Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 ± 2.3 vs. 22.6 ± 2.5 months, respectively, p < 0.01) and PFS (12.3 ± 2.1 vs. 19.1 ± 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2-1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1-2.3, p < 0.05). CONCLUSIONS Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care.
Collapse
Affiliation(s)
- O F Olmez
- Department of Medical Oncology, Uludag University Medical School, Bursa, Turkey,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Durnali A, Tokluog˘ lu S, Ozdemir N, I˙nanc M, Alkis N, Zengin N, Sonmez O, Kucukoner M, Ozkan M, Oksuzoglu B. Prognostic Factors and Treatment Outcomes of Patients with Uterine Leiomyosarcoma: A Retrospective Study of Anatolian Society of Medical Oncology. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33574-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
10
|
Ozkan M, Berk V, Kaplan MA, Benekli M, Coskun U, Bilici A, Gumus M, Alkis N, Dane F, Ozdemir NY, Colak D, Dikilitas M. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma 2012; 59:38-42. [PMID: 22103897 DOI: 10.4149/neo_2012_005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies.Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of 141 cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months (range, 2-36 months). Objective response rate was 27.3%. Total clinical benefit of the combination was 48.4%. The estimated median progression free survival and median overall survival were 5 months and 14 months, respectively. The most common Grade 3 and 4 toxicity were neutropenia and thrombocytopenia observed in 10 (27.7%) and 9 (24.9%) patients, respectively. The combination of the gemcitabine and cisplatin after taxane/anthracycline is well tolerated and seems to be effective with acceptable toxicity profile.
Collapse
Affiliation(s)
- M Ozkan
- Department of Medical Oncology, Erciyes University Medical School, Kayseri, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Demirci U, Buyukberber S, Yetisyigit T, Dizdar O, Benekli M, Alkis N, Coskun U. Trabectedin in advanced soft tissue sarcoma: case series. J BUON 2012; 17:591-592. [PMID: 23033305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The prognosis of advanced soft tissue sarcomas (STS) is poor. The median overall survival (OS) is 6 months in unresectable and metastatic STS that progress after treatment with anthracyclines and ifosfamide. Trabectedin is an alkylating agent, effective in advanced STS, especially in leiomyosarcoma and liposarcoma. In the present study, the effectiveness and safety of trabectedin was retrospectively evaluated in 8 unresectable and metastatic STS patients. Their median age was 47 years. The median progression free survival (PFS) was 3.75 months and the median OS 15 months in relapse or progression after anthracyclines and/or ifosfamide. Toxicities were mainly hematologic. In the present study, trabectedin showed efficacy in different histological subtypes of sarcomas like liposarcoma and leiomyosarcoma.
Collapse
Affiliation(s)
- U Demirci
- Department of Medical Oncology, Ataturk Education and Research Hospital, Ankara, Turkey.
| | | | | | | | | | | | | |
Collapse
|
12
|
|
13
|
Dalkilic E, Bulbul Baskan E, Alkis N, Gullulu M, Yavuz M, Dilek K, Ersoy A, Yurtkuran M. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod Rheumatol 2012; 22:738-42. [PMID: 22350572 DOI: 10.1007/s10165-011-0590-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Accepted: 12/22/2011] [Indexed: 11/26/2022]
Abstract
OBJECTIVES New adverse events are being reported with the increased use of anti-tumor necrosis factor (TNF) α therapy. We studied cases of anti-TNFα-induced psoriasis observed in our pool of 514 patients receiving anti-TNFα treatment in Turkey. METHODS Three rheumatoid arthritis patients and 3 ankylosing spondylitis patients with anti-TNFα-induced psoriasis were included in the study. All patients were examined by a dermatologist, and 3 patients underwent skin biopsy. RESULTS None of the 6 patients had preexisting psoriasis or a familial history of psoriasis. The earliest and latest occurrences of psoriatic lesions were at the 6th week and 44th month of anti-TNFα therapy, respectively. Psoriasis was severe and refractory in two patients (requiring systemic treatment), while it presented as mild in four patients. Anti-TNFα therapy was totally withdrawn in case 1. In case 2, the treatment was halted for 3 months then switched to another TNFα blocker, and case 3 was switched to another anti-TNFα treatment. The treatment was sustained in the other 3 patients (cases 4, 5, and 6). CONCLUSIONS TNFα blockers are very effective agents in the treatment of psoriasis, but it is interesting that the same molecules can, paradoxically, induce psoriasis. The occurrence of anti-TNFα-induced psoriasis in six out of 514 patients suggests that the incidence of this adverse reaction is, in fact, as not low as presumed in the literature. In some cases, a severe course of psoriasis may limit the use of these agents.
Collapse
Affiliation(s)
- Ediz Dalkilic
- Division of Rheumatology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Dalkilic E, Alkis N, Kamali S. Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases. Mod Rheumatol 2011; 22:463-6. [PMID: 21847703 DOI: 10.1007/s10165-011-0507-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2011] [Accepted: 07/25/2011] [Indexed: 11/26/2022]
Abstract
Findings of several reports suggest that rituximab, a chimeric monoclonal anti-CD20 antibody causing B-lymphocyte depletion, might represent a treatment option for people with granulomatosis with polyangiitis (GPA) (former Wegener's granulomatosis). This study presents the results of rituximab treatment in two patients with treatment-refractory GPA. First patient received rituximab for a granulomatous posterior orbital mass lesion, and eye symptoms were resolved after three courses of treatment. The second patient had eye and paranasal sinus involvement and benefited from two courses of rituximab treatment, with significant clinical improvement. Rituximab may represent an effective novel treatment for remission induction in GPA.
Collapse
Affiliation(s)
- Ediz Dalkilic
- Division of Rheumatology, Department of Internal Medicine, Uludağ Medical Faculty, Uludağ University, Bursa, Turkey.
| | | | | |
Collapse
|
15
|
Yalçintas Arslan Ü, Oksuzoglu OB, Ozdemir N, Aksoy S, Alkis N, Gok Durnali A, Kaplan MA, Gumus M, Berk V, Uncu D, Baykara M, Colak D, Uyeturk U, Turker I, Isikdogan A. Outcome of operable male breast carcinoma: One hundred eighteen patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Alkis N, Demirci U, Benekli M, Yilmaz U, Isikdogan A, Sevinc A, Ozdemir NY, Koca D, Yetisyigit T, Kaplan MA, Uncu D, Unek T, Gumus M. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. J BUON 2011; 16:80-83. [PMID: 21674854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
PURPOSE To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients. METHODS All patients in this study had previously failed oxaliplatin and irinotecan-based chemotherapy. Patients were treated with MMC (6 mg/m(2) intravenously/i.v.) on day 1 in combination with either oral UFT (500 mg/m(2)) and oral leucovorin (LV) (30 mg) on days 1-14 every 3 weeks (group A) or infusional 5-fluorouracil (5-FU) by deGramont regimen with i.v. LV (200 mg/m(2)) on days 1 and 2, every 2 weeks (group B). RESULTS Thirty-nine MCRC patients were analyzed. Twenty-two of them were in group A and 17 in group B. Thirty-three were evaluable for clinical efficacy. The clinical benefit in the intent-to-treat (ITT) population was 30.8%. Median progression free survival (PFS) was 6 months (95% confidence interval/ CI 4-8) and median overall survival (OS) 9 months (95% CI 6.5-11.5). Median PFS was 3 months (95% CI 2.4-3.6) in group A and 7 months (95% CI 5.1-8.9) in group B (p=0.009). Median OS was 7 months (95% CI 4.3-9.7) in group A and 12 months (95% CI 5.4-18.6) in group B (p=0.422). The combination of MMC and fluoropyrimidines was generally well tolerated. The most common severe toxicities were nausea and vomiting, neutropenia, hepatotoxicity and diarrhea. CONCLUSION MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients. This combination remains a viable option in these patients. However, better therapies are urgently needed.
Collapse
Affiliation(s)
- N Alkis
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Research and Education Hospital, Ankara, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Altundag MK, Icli F, Aksoy S, Oksuzoglu OB, Ozisik YY, Onur H, Utkan G, Zengin N, Alkis N, Yalcin B. Correlation of levels of serum 25-hydroxyvitamin D (25-OHD) and lymph node positivity in operable breast cancer: A Turkish Oncology Group study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Arslan UY, Tokluoglu S, Onder F, Uncu D, Uyeturk U, Turker I, Celenkoglu G, Ulas A, Alkis N. 5108 Clinical outcomes and patients characteristics of triple negative breast carcinoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71000-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
19
|
Yilmaz Y, Armagan E, Olmez OF, Esen M, Alkis N, Dolar E. Acute arsenic self-poisoning for suicidal purpose in a dentist: a case report. Hum Exp Toxicol 2009; 28:63-65. [DOI: 10.1177/0960327108097432] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
Arsenic is a classical poison that has been historically used since ancient times for homicidal purposes. More recently, episodes of deliberate or unintentional arsenic self-poisoning have been increasingly reported. We describe here a case of a 77-year old male patient with a history of major depression, who attempted suicide by ingestion of 4 g of arsenic trioxide. The man, a dentist by profession, used arsenic preparations for pulp devitalization. The patient was admitted to our hospital 5 h after arsenic ingestion with nausea and vomiting. Plain radiograph of the abdomen showed radio-opaque material in the stomach and small intestine. Nasogastric lavage, activated charcoal, and chelators were used to remove arsenic. On day 3, endoscopy disclosed the presence of gastritis and superficial ulcers. The patient developed significant anemia (Hb: 8.7 g/dL on day 7) without significant signs of hemolysis. He gradually recovered from anemia within 5 months. The patient did not suffer any adverse outcome in spite of having ingesting 4 g of arsenic, approximately 20 times the lethal dose.
Collapse
Affiliation(s)
- Y Yilmaz
- Department of Internal Medicine, Uludag University Medical School, Bursa, Turkey
| | - E Armagan
- Department of Emergency Services, Uludag University Medical School, Bursa, Turkey
| | - OF Olmez
- Department of Internal Medicine, Uludag University Medical School, Bursa, Turkey
| | - M Esen
- Department of Emergency Services, Uludag University Medical School, Bursa, Turkey
| | - N Alkis
- Department of Internal Medicine, Uludag University Medical School, Bursa, Turkey
| | - E Dolar
- Department of Gastroenterology, Uludag University Medical School, Bursa, Turkey
| |
Collapse
|
20
|
Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, Alkis N. Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma. Exp Oncol 2006; 28:326-7. [PMID: 17285120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
UNLABELLED The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL). METHODS The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n=7; stage II, n=4; stage III, n=7; stage IV, n=2) was analyzed using Brookfield DV-II + (USA) machine. RESULTS Blood viscosity in NHL patients (median: 5.5+/-1.46 miliPascal) inversely correlated with lactatdehydrogenase (LDH) level, international prognostic index (IPI) score, and stage (p=0.02, r=-0.51; p=0.03, r=-0.63; and p=0.04, r=-0.45, respectively) and positively correlated with hemoglobin level (p=0.02, r=0.65)). CONCLUSION According to our data, blood viscosity may be considered as a follow up marker in NHL patients along with LDH level or sedimentation rate.
Collapse
Affiliation(s)
- G Utkan
- Ankara Oncology Research and Training Hospital, Ankara, Turkey.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Tuzuner A, Ucok C, Kucukyavuz Z, Alkis N. O.172 Post-operative analgesic effects of preemptive diclofenac sodium and tramadol in bimaxillary osteotomy. J Craniomaxillofac Surg 2006. [DOI: 10.1016/s1010-5182(06)60201-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|